Clinical-stage biotechnology company Tectonic Therapeutic Inc. (TECX) is building its pipeline around a single, urgent truth: pulmonary hypertension doesn't wait. It progresses quietly, often masked by fatigue or shortness of breath, until the body can no longer compensate. For patients with interstitial lung disease or heart failure, the stakes are immediate, and the options are limited.
TX45 is being developed to meet that moment. Not as a theoretical solution, but as a candidate already showing signs of impact.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com